#United Kingdom #CiteAb #Bath #Life Science Research #Top 100 Reports

CiteAb's 2026 Top 100 Reports: An Insight into Life Science Research Tools

On October 6, 2026, CiteAb published their anticipated annual Top 100 Reports, which list the most-cited research tools utilized in life sciences. These reports offer a window into the evolving landscape of suppliers and highlight emerging trends that are shaping the field. Spanning research antibodies, proteins, kits, assays, cell lines, bioactive small molecules, and various instruments, these reports provide significant insights based on comprehensive analysis directly extracted from peer-reviewed scientific literature.

Expanding Supplier Landscape

One of the key findings from this year's report is the expanding competition among suppliers. The number of suppliers featured has increased across multiple categories. In the realm of bioactive small molecules, 15 suppliers made it into the Top 100, up from previous years, while 13 suppliers were recognized in antibodies and 22 in kits, highlighting a significant growth from the last assessment. Moreover, the newly launched instruments report included 24 suppliers, with notable mentions of Waters Biosciences and ZEISS, both of which placed multiple instruments into the Top 100 list.

Stability and New Entrants

While the report showcases a variety of emerging suppliers and products, it also reveals that established products continue to hold their ground. Leaders such as QIAGEN's RNeasy Mini Kit, Cell Signaling Technology's Anti-rabbit IgG HRP-linked antibody, and the HEK293 cell line group maintained their high rankings, indicating their ongoing importance in the research community. Interestingly, the Kits & Assays category welcomed 14 new products in its Top 100, further proving that even in mature markets, there is always room for innovation and growth. Among the new entries, Proteintech's HRP-conjugated Goat Anti-Rabbit IgG(H+L) managed to break into the Top 10 antibody rankings, underscoring its rising popularity.

Among the top cited items are Alt-R S.p. Cas9 Nuclease VS3, a gene editing tool from Integrated DNA Technologies, which made its way into the proteins category. Cancer therapy compounds have also been notable in research tool applications, as they figured prominently in the bioactive dataset. The representation of cancer-related cell lines in the Top 100 further emphasizes the growing focus on cancer research within the scientific community.

Insights from CiteAb's CEO

Dr. Andrew Chalmers, CEO of CiteAb, remarked on the importance of the reported data, stating, "Our database provides a unique perspective on market trends. Citations serve not only as indicators of product sales but also reflect the products that have made a significant impact in past research. The Top 100 reports highlight the vendors and products that contribute substantially to published research, aiding researchers in their quests for knowledge."

Ultimately, both suppliers and investors can gain valuable insights from the Top 100 reports, paving the way for a deeper understanding of where the demand is shifting within the life science research market. These reports not only help in identifying key players in the field but also in recognizing the innovative products that are on the rise.

For those interested in further exploring the key findings, CiteAb has made the data available for download, including a thorough overview of the methodology and analysis. Visit CiteAb’s website for more details and access to this vital information.

About CiteAb

CiteAb is committed to fostering scientific advancement by delivering world-class data that accelerates research. With a database encompassing 18 million reagents and their use across 41 million publications, their Explore Platform assists researchers in efficiently locating the right products for their work. This data also serves reagent suppliers, investors, publishers, and pharmaceutical and biotech companies globally. To delve deeper into their services and offerings, you can explore more at www.citeab.com.